|Bid||1.25 x 1800|
|Ask||0.00 x 4000|
|Day's Range||1.1234 - 1.2500|
|52 Week Range||1.0000 - 2.7500|
|Beta (3Y Monthly)||2.42|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.00|
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that it has entered into a definitive agreement with a single institutional investor to receive gross proceeds of approximately $2.35 million. In connection with the offering, the Company will issue 2,238,096 registered American Depository Shares (ADSs) of Can-Fite at a purchase price of $1.05 per ADS in a registered direct offering.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced new pre-clinical findings demonstrating that Namodenoson, inhibits lipid production and fat accumulation in adipocytes (lipid producing cells). These findings together with the excellent safety profile of Namodenoson support its potential utilization as an anti-obesity drug. New pre-clinical studies of Namodenoson showed a significant decrease in lipid production and fat accumulation utilizing 3T3-L1 adipocytes, functioning as lipid producing cells and are also responsible for fat storage.
Can-Fite’s near term milestones include data release from a Phase II study with its Namodenoson drug in patients with advanced liver cancer which is expected in Q1/19. In addition, the Company is actively enrolling NAFLD/NASH patients for a Phase II study of Namodenoson.
The agreement will support research directed by Scott Friedman, M.D., Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at the Icahn School of Medicine. The research is aimed at transcriptomic and molecular analyses to further explore the mechanisms of action of Namodenoson (CF102) in human hepatic stellate cells in order to clarify its effect on fibrogenesis that occurs in non-alcoholic steatohepatitis (NASH).
Revenues for the Nine Months Ended September 30, 2018 Were $3.5 Million Compared to $0.7 Million for the Same Period in 2017
PETACH TIKVA, Israel-- -- Dr. Josep Llovet is a Key Opinion Leader in the field of liver diseases Data from Phase II study in advanced liver cancer are expected during Q1 2019 Can-Fite BioPharma Ltd . , a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced that Professor Josep Llovet, an experienced leader with deep ...
Namodenoson has received Fast Track Status in the U.S. and Orphan Drug Designation in Europe and the U.S. In order to maintain the statistical integrity of the trial as well as adhere to the principles of Good Clinical Practice, the Company estimates that it will un-blind the data during Q1/19.
Dr. Fishman will present the molecular mechanism mediating the anti-cancer effects of Namodenoson and will describe clinical data from the Company’s earlier Phase I/II liver cancer study. In addition, she will present the status of the current Phase II study in patients with advanced hepatocellular carcinoma, Child Pugh B. Patients with advanced HCC, Child Pugh B, who failed Nexavar (sorafenib) as a first line treatment are treated twice daily with 25 mg of oral Namodenoson or placebo using a 2:1 randomization.
“I am pleased to be invited to speak at NASH Summit Europe and to share Can-Fite’s Namodenoson molecular mechanism of action in inhibiting the manifestations of NAFLD/NASH. Namodenoson represents a novel therapy approach for the treatment of NASH and its precursor, non-alcoholic fatty liver disease (NAFLD).
Can Fite will present data generated recently in histological studies utilizing the CCL4 NAFLD/NASH model, demonstrating a significant decrease in liver fibrosis upon chronic treatment with Namodenoson, as measured by Sirius Red staining followed by morphometric digital analysis. Similar data were also reproduced in a human hepato-stelatte cell line demonstrating significant decrease in α-SMA expression level, a specific fibrosis bio-marker.
Namodenoson has received Fast Track Status in the U.S. and Orphan Drug Designation in Europe and the U.S. Top line efficacy results are expected by end of year. The global Phase II study is being conducted in the U.S., Europe and Israel.
- Company signed a multi-million dollar development and distribution agreement for Piclidenoson and Namodenoson in China with CMS Medical and received an upfront payment of $2M
Can-Fite BioPharma (CANF), today announced it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City. Motti Farbstein, CFO of Can-Fite, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.rodmanevents.com ) to register for the conference.
The Comfort™ Phase III Psoriasis study, is designed to evaluate the efficacy and safety of daily Piclidenoson, administered orally compared to Apremilast (Otezla®) and placebo, in 407 patients with moderate-to-severe plaque psoriasis. The study will be conducted in 5 countries in Europe, Israel and Canada.
Can-Fite recently announced entering into a development, registration and marketing agreement with CMS for the exclusive right of Can-Fite’s lead drug candidates, Piclidenoson (CF101), for the treatment of rheumatoid arthritis and psoriasis & Namodenoson (CF102) for the treatment of advanced liver cancer and NAFLD/NASH in China (including Hong Kong, Macao and Taiwan). The recently signed CMS agreement adds to the agreements that the Company already has in place with Cipher Pharmaceuticals (for the distribution of Piclidenoson in Canada for rheumatoid arthritis and psoriasis), Kwang Dong Pharmaceutical (for the distribution of Piclidenoson in South Korea for rheumatoid arthritis), Chong Kun Dang (for distribution of Namodenoson in South Korea for treatment of liver cancer) and Gebro Pharma (for the distribution of Piclidenoson in Spain, Switzerland and Austria).
Upfront and milestone payments total up to $74.5M plus double-digit royalties
Aug 6 (Reuters) - China Medical System Holdings Ltd : * THROUGH UNIT SIGNED A LICENSE, COLLABORATION AND DISTRIBUTION AGREEMENT WITH CAN-FITE BIOPHARMA LTD Source text for Eikon: Further company coverage:...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Netflix, Inc. (NASDAQ: NFLX ) was trading lower by ...
The Company has been investigating compounds that target the A3 adenosine receptor (A3AR) and the Company’s CF602 drug candidate previously demonstrated a robust positive effect in the treatment of erectile dysfunction in preclinical studies. Can-Fite has been granted a similar patent in the U.S. for both the method for treating erectile dysfunction with different A3 adenosine receptor (A3AR) ligands and a composition of matter for allosteric compounds.
PETACH TIKVA, Israel-- -- A third party validation for the Can-Fite scientific approach to combat Liver Cancer A Phase II study in patients with advanced liver cancer is currently ongoing with Namodenoson and completed patients’ enrollment Namodenoson has an Orphan Drug Designation in Europe and the U.S., as well as Fast Track Status in the U.S. Can-Fite BioPharma Ltd . , a biotechnology company advancing ...
Accumulated safety data to date continues to indicate a favorable safety profile, with no clinically significant novel or emerging events attributed to chronic treatment with Namodenoson. Michael Silverman, MD, FACP, Can-Fite’s Medical Director says, “While the final analysis of this trial, based on survival, has been delayed past our original projections, we are very happy that the reason for this is the unexpected longevity of patients enrolled into this trial.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Enphase Energy Inc (NASDAQ: ENPH ) stock was trading ...
The data came out of a recently signed collaborative research agreement with Hadassah Medical School, directed by Rifaat Safadi, M.D., Head of the Liver Unit, Gastroenterology and Liver Diseases, Division of Medicine at Hadassah Medical Center and Professor of Internal Medicine, Bowel, Liver Disease, and Metabolic Syndrome at Hebrew University in Israel.
Can-Fite BioPharma Ltd. , a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, today reported financial results for the three months ended March 31, 2018 and provided clinical and corporate updates.
Can-Fite BioPharma Ltd. , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory and liver diseases, today announced the publication of a paper entitled “Inhibition of IL-17 and IL-23 in Human Keratinocytes by the A3 Adenosine Receptor Agonist Piclidenoson” in the Journal of Immunology Research, a peer-reviewed, online open access journal.